Despite these advances, the lack of approved targeted treatments (other than mTOR inhibitors and anti-HER2 agents) makes the genomic profiling of breast cancer less attractive compared with other tumours, such as lung cancer. The gene discussed is ERBB2; the disease is neoplasm.